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1. Introduction
Cystic Fibrosis (CF) is the most common life-threatening inherited disease in the United
Kingdom, affecting over 9,000 people, 56% of which are 16 years or older (UK CF Registry
Annual Data Report 2009). Life expectancy currently remains well below the general popu‐
lation, but with improvement of care most CF patients born after 1980 are expected to reach
adulthood. Much of the morbidity and mortality associated with CF are related to the respi‐
ratory system (Goss & Burns, 2007).
Recurrent acute infective pulmonary exacerbations are one of the most important features of
CF. Pulmonary exacerbations are common events throughout the lifetime of a patient with
CF. Frequent exacerbations are associated with impaired quality of life and accelerated de‐
cline in lung function (Marshall, 2004; Britto et al., 2002; Liou et al., 2001; Ramsey, 1996).
Statistical models have demonstrated that frequent pulmonary exacerbations are also associ‐
ated with premature mortality (Liou et al., 2001).
Preventing and treating pulmonary exacerbations promptly and appropriately are therefore
key therapeutic goals of the CF community that clinicians endeavour to employ in the effort
to positively impact on long term outcomes, survival and quality of life of CF patients.
2. The pathophysiology of CF lung disease
Despite CF being one of the most studied and understood genetic diseases, the exact patho‐
physiology of recurrent CF pulmonary exacerbations is still not completely understood. The
most accepted hypothesis to explain how the primary defect in CF, the mutations in the
© 2013 Sequeiros and Jarad; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
cystic fibrosis transmembrane conductance regulator gene (CFTR), leads to the colonisation
of the airways by bacteria, chronic infection and inflammation and ultimately airway injury
is the “low volume hypothesis” (Boucher, 2004).
The airways are covered by airway surface liquid, composed by two separate fluid layers, a su‐
perficial mucus layer and an underlying lubricating pericellular environment near the cell sur‐
face. A thin layer of surfactant separates the mucus and the periciliary fluid layer (figure 1).
The mucus layer is produced by goblet cells and submucosal glands and is composed of wa‐
ter, carbohydrates, proteins and lipids, extending from the intermediate airways to the up‐
per airways. It normally is composed of a network of mucous glycoproteins or mucin. Its
adhesive characteristic means that the mucus layer binds and traps deposited particles and
its viscoelastic properties facilitate cilia movement into transporting mucus and also its
clearance by cough. Mucus containing cellular debris and possible trapped microorganisms
is transported from the lower respiratory tract to the pharynx by mucociliary clearance and
air flow (Rubin, 2002). Mucus clearance is considered a most important innate airway de‐
fence mechanism (Randell & Boucher, 2006; Knowles & Boucher, 2002), and disruption of
the normal mucus secretion and mucociliary clearance impairs lung defence and increases
the risk of infection.
The periciliary fluid provides a watery environment that enables the cilia to beat and propel the
mucus away towards the upper airways. Appropriate clearance and hygiene maintenance of
the respiratory tract requires coordinated interaction of the mucus and periciliary layers and
for this to be effective, adequate hydration of the near-cell airway surface is critical.
Figure 1. The fluid surface area in normal patients (a) and in patients with CF (b). The epithelial cells are covered by
two layers of fluid – a serous layer (white band) and a mucous layer (grey area). In CF patients and due to the disease
process, both layers shrink and the shape of the cilia and its movement are adversely affected.
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The volume of the periciliary airway surface fluid is normally precisely regulated and is critical
for efficient mucus flow and elimination. In the normal airway epithelium, the amount of fluid
is determined by a combination of ion channels that promote the secretion of salt and water,
such as the CFTR and alternative anion channels, and others that promote absorption of so‐
dium and fluid, such as epithelial sodium channels (ENaC) in the apical cell membrane. The
CFTR also acts as a conductance regulator, influencing and down regulating the latter.
In the CF epithelium, in consequence of the CFTR mutations, the CFTR gene product is faul‐
ty, whilst in normal conditions it is a transmembrane protein that functions as a chloride
channel. The CFTR down regulatory function of ENaC activity is absent or compromised,
resulting in abnormal ion transport properties due to the combined defects of accelerated so‐
dium transport and failure to secrete chloride, resulting in overall increased absorption of
sodium and fluid from the airway surface and consequently reduced, low volume of the air‐
way surface liquid (Guggino & Guggino, 2000).
The loss of functional height of the periciliary layer in which the cilia beat, defined by the
length of extended cilia, interferes with cilia motion and causes impaired ciliary function, re‐
sulting in slower mucociliary clearance with accumulation of mucus with trapped debris,
microorganisms and airway secretory products, such as cytokines (e.g., interleukin-8), neu‐
trophil proteases and growth factors that promote airway inflammation and mucus cell hy‐
perplasia. In consequence of increased number of mucus secreting goblet cells, there is
persistent mucin secretion, which generates high volume of thick, inspissated mucus, which
adheres to and obstructs the airways and is resistant to cough clearance and is an ideal site
and reservoir for bacterial growth. The poor liquid content and hypoxic environment in
these thick mucus plaques promote biofilm bacterial formation and bacterial overgrowth.
Mucus stasis and the presence of accumulated secretory products and bacteria triggers the
recruitment of neutrophils to the airways and the release of pro-inflammatory cytokines,
which lead to a vicious cycle of inflammation, airway obstruction, chronic infection, repeat‐
ed pulmonary exacerbations and resultant airway tissue damage and loss of lung function
(Frizzell & Pilewski, 2004).
3. Microbiology in the CF lung disease and relationship with pulmonary
exacerbations
Pulmonary exacerbations in CF are caused by recognised typical pathogens that are acquired
following a characteristic age-dependent pattern (figure 2). Whilst still very young, CF patients
suffer their first infections most frequently caused by Staphylococcus aureus and Haemophilus in‐
fluenzae. S. aureus is often the first organism isolated from children with CF, but the role of this
bacteria in the pathogenesis of CF remains under debate as studies reveal conflicting results in
regards to clinical benefits from anti-staphylococcal therapy (Smyth & Walters, 2003; Lyczak et
al., 2002). Non-typeable H. influenzae is also commonly cultured from CF children as early as in
their first year of life, but although it can cause exacerbations in patients with non-CF bron‐
chiectasis (Barker, 2002), its role in CF is still unclear (Goss & Burns, 2007).
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Other relevant pathogens in CF usually cultured later in the course of the disease include
Burkholderia cepacia complex, Stenotrophomonas maltophilia and Achromobacter xylosoxidans.
The B. cepacia complex has at least 10 distinct genomovars and is related with rapid clinical
deterioration. The most virulent and transmissible form is the genomovar III, B. cenocepa‐
cia, due to its well recognised association with severe necrotising pneumonia and death first
described over 20 years ago (Isles et al., 1984). S. maltophilia and A. xylosoxidans are more
prevalent than the B. cepacia complex, but seem to be less virulent, although their role in the
pathogenesis of the CF lung is not yet completely understood (Goss et al., 2002).
Figure 2. Prevalence of respiratory pathogens according to patient’s age. Data from Cystic Fibrosis Foundation Patient
Registry, 2010 Annual Data Report.
Pseudomonas aeruginosa is considered to be the most important pathogen in CF. By the time
patients reach adulthood, up to 80% of them become infected with P. aeruginosa. The trans‐
formation of P. aeruginosa from the non-mucoid to the mucoid strains, which often occurs
during adolescence years (figure 3a), is pivotal and is known to be associated with clinical
(figure 3b) and radiological deterioration (figure 3c) (Li et al., 2005). At initial colonisation, P.
aeruginosa presents a phenotype similar to environmental strains, but this changes dramati‐
cally with time and prolonged infection as P. aeruginosa has the potent ability of quorum
sensing which leads to biofilm formation (Drenkard & Ausubel, 2002). Biofilm is a matrix of
proteins, carbohydrate and collagen and muco-polysaccharide within which the bacteria re‐
side. This layer is often called alginate formation. The formation of alginate biofilm has 3 im‐
portant consequences:
1. The bacteria are protected from antibiotics, which increases the minimal-inhibitory con‐
centration.
2. The film reduces the activity of aminoglycosides and beta-lactam antibiotics by chang‐
ing the pH of the respiratory mucosa and by production of beta-lactamase – ironically,
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mucoid P. aeruginosa tend to exhibit greater in vivo sensitivity to antibiotics than non-
mucoid strains in the same patient.
3. The biofilm formation is highly immunogenic and tends to accelerate structural lung
damage leading to significant histological and radiological changes.
The incidence and clinical impact of mucoid P. aeruginosa (figure 3a) in the sputum of a co‐
hort of patients with CF according to age. The emergence of these bacteria is associated with
decline in FEV1 (figure 3b) and worsening of radiograph appearance (figure 3c). (Adapted
from Li et al., 2005).
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Figure 3. (a): Proportion (%) of P. aeruginosa with mucoid strains per age group. (b): Change in FEV1 for the same CF
group as in 3a. (c): Change in the chest radiograph appearance in the same CF group as in 3a
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4. Acute pulmonary exacerbations in CF
Pulmonary exacerbations in CF are an important feature of the disease. Frequency of pulmo‐
nary exacerbations is associated with accelerated decline in lung function tests, impaired
quality of life and premature mortality. Nevertheless, defining what constitutes a pulmona‐
ry exacerbation remains controversial.
To date there is not yet a consensus or a standardised diagnostic criteria as to what clinically
characterises pulmonary exacerbations in CF (Abbot et al., 2009; Dakin et al., 2001), but all
descriptions point to that patients present with a combination of symptoms. Although, not
stated clearly, the implication is that symptoms during exacerbations are greater than symp‐
toms during ‘disease stability’.
Pulmonary exacerbations are usually described by patients in subjective terms as an increase
in one or more respiratory symptoms, such as cough, sputum volume, viscosity and colour
change, breathlessness; altered systemic symptoms, such as increased fatigue, decreased ap‐
petite and energy levels. This is usually, but not always associated with an increase in objec‐
tive clinical signs and changes in biomarkers. These included: weight loss, tachypnoea,
tachycardia, decreased lung function parameters, chest radiographic changes and raised se‐
rum inflammatory markers (Ramsey et al., 1999; Fuchs et al., 1994).
The lack of a standardised definition is also present when it comes to classifying pulmonary
exacerbations according to their severity. Pulmonary exacerbations are broadly divided into:
a) mild exacerbations requiring treatment with oral antibiotics and b) severe exacerbations
needing treatment with intravenous (IV) antibiotics. It also remains unclear if mild exacerba‐
tions are the originators of severe infections, if they are earlier milder versions of severe pul‐
monary exacerbations or in fact differentiated clinical episodes with no correlation between
mild and severe infections (Goss & Burns, 2007).
Despite the lack of agreement, several diagnostic systems are described in the literature and
used in CF clinical trials, such as the Fuchs et al. (1994) Pulmozyme® study and the Ramsey
et al. (1999) inhaled Tobramycin study diagnostic criteria, and the consensus document by
the US CF Foundation, 1994 (tables 1, 2 and 3).
These definitions, often called “symptom-related definitions”, although widely used, have 3
shortcomings:
1. They do not account for differences of CF pulmonary exacerbations in children and
adults. For example, the presence of fever and acute changes in chest radiographs are
often seen in children, but not in adults.
2. They do not quantify symptom severity and do not give allowance for increased severi‐
ty of a single symptom, which may make patients seek medical consultation and receive
treatment. For example, marked increase in breathlessness, significant increase in cough
production of viscous sputum or increased lethargy alone could be a single symptom
that may constitute an exacerbation requiring treatment with antibiotics.
3. The above definitions do not stipulate that increase in symptoms should be sustained and
should be beyond the natural fluctuation of symptoms encountered in most CF patients.
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- Increased cough
- Dyspnoea or increased respiratory rate
- Change in appearance of sputum (i.e. consistency, increased purulence or volume)
- Lassitude and decreased exercise tolerance
- Decreased appetite
- Absenteeism from work or place of education
- Fever (>38oC)
- Progressive physical findings (crackles or wheeze) on chest auscultation
- New infiltrate on the chest X-ray
- Deterioration of 10% or more of the highest FEV1 measured in the last 6 months
Table 1. Signs and symptoms of pulmonary exacerbations as agreed by the consensus document of the US Cystic
Fibrosis Foundation, 1994. Typically a combination of 3 or more signs and symptoms represent a pulmonary
exacerbation.
- Change in sputum
- New or increased haemoptysis
- Increased cough
- Increased dyspnoea
- Malaise, fatigue, or lethargy
- Temperature above 38°C
- Anorexia or weight loss
- Sinus pain or tenderness
- Change in sinus discharge
- Change in physical examination of the chest
- Decrease in pulmonary function by 10% or more from a previously recorded value
- Radiographic changes indicative of pulmonary infection
Table 2. Fuchs et al. (1994) Pulmozyme Study: “Exacerbation of respiratory symptoms”: a patient treated with
parenteral antibiotics for any 4 of the following 12 signs or symptoms:
- Fever (oral temperature >38°C)
- More frequent coughing (increase of 50%)
- Increased sputum volume (increase of 50%)
- Loss of appetite
- Weight loss of at least 1 kg
- Absence from school or work (at least 3 or preceding 7 days) due to illness
- Symptoms of upper respiratory tract infection
- These symptoms had to have been associated with at least 1 of the following 3 additional criteria:
- Decrease in FVC of at least 10%
- An increase in respiratory rate of at least 10 breaths/min
- A peripheral blood neutrophil count of 15,000/mm3
Table 3. Ramsey et al. (1999) Inhaled Tobramycin Study: Pulmonary exacerbation indicated by at least 2 of the
following 7 symptoms during the study.
Cystic Fibrosis Pulmonary Exacerbation – Natural History, Causative Factors and Management
http://dx.doi.org/10.5772/54336
179
In a retrospective analysis of 77 pulmonary exacerbations in 88 adult patients, the authors
found that IV antibiotics were given to 18 patients (24.4%) whose symptoms did not meet
the US CF criteria (table 1) (Jeffcote et al., 2004). This would suggest that nearly one quarter
of patients presented with sufficiently severe symptoms to warrant treatment with IV antibi‐
otics, although the combination of factors did not meet the pre-designed criteria.
For this reason, we explored another definition of pulmonary exacerbations, which resem‐
bled the internationally accepted definition of exacerbation in chronic obstructive pulmona‐
ry disease (COPD). In such patients, pulmonary exacerbations are defined as “an event in
the course of the disease in which there is a sustained worsening of the patient’s respiratory
symptoms from the stable state that is beyond normal day-to-day variations, that is acute in
onset and necessitates escalation of treatment”. This is often termed as “an action-defini‐
tion” in which an exacerbation is regarded to be present when the following 3 criteria are
met:
1. The increase in respiratory symptoms is sustained (lasting 2-3 days).
2. The symptoms are subjectively more than the patient’s own baseline symptoms –
enough so that the patient seeks medical treatment.
3. The symptoms are objectively compelling to the physicians as to be deemed to require
escalation of treatment with antibiotics.
This definition has its problems too. Patients have different thresholds for seeking medical
care and therefore some may present more frequently than others, despite similar severity of
symptoms. Another problem is that in countries where patients have to pay for their treat‐
ment, financial restraint may prevent patients from seeking medical treatment for exacerba‐
tion of symptoms.
To try to resolve this issue, Sarfaraz et al. (2010) conducted a study using electronic remote
daily telemonitoring of symptoms in a cohort of adult CF patients. The study highlighted
several issues in the management of CF exacerbations. Out of the 51 patients enrolled in the
study, 32 (63%) patients were subsequently excluded as their recordings were not frequent
enough to form a baseline data or insufficient to look into the natural history of the disease
(Figure 4). Furthermore, for the remaining 19 patients who completed the study, an average
of only 60% of the total number of study days was recorded.
Despite these significant deficiencies, there were enough CF pulmonary exacerbations for
analyses. The authors noticed that 75% of all CF exacerbations had a “prodromal” phase in
which one or more than one symptom increased in the 2 weeks prior to exacerbations (Figure
5).
In order to examine whether the problem with daily recording was related to the introduc‐
tion of a modern system, a parallel study in COPD patients was carried out (Sund et al.,
2009). A systematic comparison between the 2 groups was later published (Jarad & Sund,
2011). The comparison revealed that the dropout rate was much smaller for COPD patients,
who recorded daily data in 77% of the total number of study days (figure 6). In accordance
with the higher recording rate by COPD patients, the number of early exacerbations diag‐
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nosed was higher than that in CF patients and the number of hospitalisation was much re‐
duced in COPD patients (but not in CF patients) compared to a similar period without daily
monitoring the year prior to the study.
Figure 4. An example of the daily recording of a 23 male CF patient. The Y axis is the score of each symptom (cough,
sputum, breathlessness and fatigue). For FEV1, the Y axis is the value in litres. The time line on the X axis is divided in
weeks. Note that only 9 days were recorded by the patients out of possible 49 days (7 weeks). This patient was with‐
drawn from the study.
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Figure 5. A 24 year old female CF patient who had a pulmonary exacerbation (marked with the red vertical line) de‐
fined by the decline in FEV1. Note that there was a “prodromal phase” manifested by increase in cough and fatigue
within the 2 weeks prior to the exacerbation.
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Figure 6. A recording from a patient with COPD. The red line represents an exacerbation defined as 15% decline in
FEV1 below the baseline. Note the patient performed a daily recording without interruption allowing a proper identi‐
fication of acute exacerbation.
Differences between the two groups may not only reflect differences in disease processes
and age groups. They may also disclose the differences in the system of care for CF patients
who tend to have a privileged access to hospital care through direct contact with a CF multi‐
disciplinary team. This is not available to COPD patients, whose contact with healthcare
takes place through a general practitioner.
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5. Causes of pulmonary exacerbations
Whilst still not completely understood, causes of pulmonary exacerbations are most likely
multi-factorial, and may differ amongst patients.
Nevertheless, CF pulmonary exacerbations are probably a consequence of a loss of equilibrium
between host defence mechanisms and the airway microorganisms. It is believed that viruses,
including respiratory syncytial virus, have a role in pulmonary exacerbations (Hiatt et al.,
1999), and whilst these have also been associated with the acquisition of new organisms, for the
majority of adult CF patients a new pulmonary exacerbations seems to be caused much more
commonly by a clonal expansion of already present colonising bacteria (Aaron et al., 2004).
Only rarely are pulmonary exacerbations a consequence of newly acquired bacteria. The in‐
crease in bacterial load in conjunction with an inflammatory response of the airways result
in a local influx of polymorphonucleocytes and the release of inflammatory mediators such
as interleukins – (IL) 8, 6, 1β, tumour necrosis factor alpha (TNF-α), leukotriene B4 and free
neutrophil elastase.
Treatment with antimicrobial agents is associated with decreased levels of inflammatory
mediators and bacterial density and improvement of symptoms and lung function parame‐
ters (Colombo et al., 2005; Ordonez et al., 2003; Sagel et al., 2001; Bonfield et al., 1995; Kon‐
stan et al., 1994; Konstan et al., 1993). This suggests that the increased density of microbes
plays an important role in pulmonary exacerbations. What remains unclear is the lack of
ability of powerful antibiotics given at great doses in eradicating pulmonary microbes in CF
patients. Rather it would seem that the role of antibiotics is akin to cutting the grass in a
front garden lawn, only for the grass to grow again.
6. Epidemiology and risk factors
CF pulmonary exacerbations are common and the impact they have on patient care, espe‐
cially in terms of labour intensiveness, is the main reason for the establishment of CF centres
and teams. In addition, treatment of pulmonary exacerbations accounts for a significant part
of the cost of CF care.
In a cross sectional study on adult CF patients in the South West of England, Jarad & Giles
(2008) found that a significant number of patients did not suffer from any pulmonary exac‐
erbation. Many patients, however, suffered from at least one exacerbation every year (figure
7). When examining risk factors of exacerbations, reduced FEV1 (figure 8), infection with P.
aeruginosa (figure 9) and cystic fibrosis related diabetes (CFRD) were correlated with in‐
creased rate of exacerbations (figure 10) (adapted from Jarad & Giles, 2008). Remarkably, ge‐
netic profile, diagnostic sweat chloride, body mass index, age and gender did not correlate
with frequency of pulmonary exacerbations.
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In addition, this study concords with previous studies that have demonstrated factors associat‐
ed with pulmonary exacerbations, such as young age, female gender, lower FEV1, CFRD and
previous history of multiple exacerbations (Block et al., 2006; Marshall et al., 2005).
Conversely inhaled antibiotics such as aminoglycosides, oral macrolides, mucolytics and in‐
haled hypertonic saline have been shown to reduce the rate of pulmonary exacerbations
(Gibson et al., 2003; Saiman et al., 2003; Ramsey et al. 1999; Fuchs et al., 1994), presumably
by reducing the bacterial load and inflammation and clearing the airways, reducing the vol‐
ume of retained secretions.
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Figure 7. A histogram of the number of exacerbations experienced in one year by 680 patients in the South West of
England.
Figure 8. Patients with and without chronic infection with P. aeruginosa in 4 annual exacerbations category. Note that
the proportion of those who are infected is greater with increased frequency of annual exacerbations. PExs = number
of pulmonary exacerbations per year.
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Figure 9. Annual exacerbation frequency increases in patients with lower FEV1. N = number of patients per group.
PExs = number of pulmonary exacerbations per year.
Figure 10. Proportion of patients with CFRD and without CFRD according to annual exacerbation frequency. PExs =
number of pulmonary exacerbations per year.
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7. What affects the time until the subsequent CF pulmonary
exacerbations?
Time from the end of one pulmonary exacerbation until the subsequent exacerbation (time
until the next exacerbation) is a significant health outcome and one of the significant end
points in many CF clinical trials. Shorter periods until the following exacerbation is a marker
of increased impact of disease on patients. In a prospective study on 170 exacerbations in 58
adult CF patients, (Sequeiros & Jarad, 2012), the median time until subsequent exacerbations
was 112 days, although this varied considerably (figure 11).
Figure 11. A histogram of time until the next exacerbation on the X axis. Median time (red vertical line) was 121 days,
although this varied considerably. Those patients who did not have an exacerbation during the subsequent year after
the first pulmonary exacerbation were regarded to have a time until the next exacerbation of 360 days (adapted from
Sequeiros & Jarad, 2012).
Factors affecting shorter periods until the following pulmonary exacerbation were exam‐
ined, including age, lung disease severity, CF related complications (CFRD, allergic bron‐
cho-pulmonary aspergillosis (ABPA)), chronic infection with P. aeruginosa and site of
administration of antibiotics – either home or in hospital. In addition, symptom scores, lung
function tests and inflammatory biomarkers at the end of the IV treatment were examined.
When analysing individual variables, patients with lower FEV1, greater symptom scores
and higher C-reactive protein (CRP) at the end of the exacerbation treatment were associat‐
ed with shorter time until the next exacerbation. Also patients with ABPA and CFRD had a
shorter time until the next exacerbations than those without. After adjustments to confound‐
ing factors, however, older CF patients and those with lower FEV1 at the end of course of
treatment were found to be the two independent risk factors.
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8. Management of pulmonary exacerbations
The mainstay of treatment of pulmonary exacerbations is administration of antibiotics. For
mild exacerbations oral antibiotics are usually administered – mainly quinolones. This ap‐
proach is based on little evidence, since a large proportion of patient have quinolone resist‐
ant P. aeruginosa.
More severe exacerbations are prescribed IV antibiotics. As most patients with frequent ex‐
acerbations commonly grow P. aeruginosa in their sputum, CF physicians prescribe two anti‐
biotics aiming to effectively decrease the bacterial load and reduce the probability of
developing antibiotic resistance. The choice of antibiotic class range would often include an
aminoglycoside (tobramycin, gentamycin and amikacin) and a beta-lactam (ceftazidime, az‐
treonam, pipracillin or ticarcillin) or a quinolone (ciprofloxacin). In more recent years, carbo‐
penims (imipenim or meropenim) are being more frequently used. Occasionally IV colistine
is prescribed in cases of bacterial resistance. The duration of treatment is often 2 weeks.
The doses of antibiotics given for CF patients are often larger than those given to other respi‐
ratory and non-respiratory infections. This is, theoretically, thought to be necessary due the
high bacterial load in the damaged and inflamed lungs and the difficulty of antibiotics pene‐
trating the thick layer of inspissated sputum to reach the bacteria – in particular when mu‐
coid P. aeruginosa is present.
Lack of evidence of how to optimally manage CF pulmonary exacerbations is, in part, due to
the fact that the determinants of the successful outcome of treatment of an exacerbation have
not yet been clearly identified. In most CF centres improvement in general clinical status
and in lung function tests are accepted to determine the ‘end’ of the exacerbation. For those
patients who do not show sufficient improvement in the opinion of the treating physicians,
the course of antibiotics is either extended or the combination of antibiotics is changed. De‐
spite its shortcomings, this approach has been endorsed in a consensus document published
by the UK CF Trust (UK CF Trust Antibiotic Guidelines 2008).
For pulmonary exacerbations treated with IV antibiotics, the combination of choice is often
determined on arbitrary grounds. Previous in vitro sensitivity and previous clinical response
normally determine the choice of antibiotics. However, several retrospective and prospec‐
tive studies found that the concordance of in vitro sensitivity did not affect any of the out‐
comes of the CF exacerbations, including lung function tests and the time until the
subsequent pulmonary exacerbation (Jarad et al., 2007; Foweraker et al., 2005).
Frequent and longer courses of IV treatment, particularly with aminoglycosides, have been
shown to be associated with renal impairment (Smyth et al., 2008; Al Aloul et al., 2005) and
ototoxicity (Mulheran et al., 2001; Scott et al., 2001), as well as increased rate of antibiotic al‐
lergy (Moss et al., 1984). In addition, extension of duration of IV antibiotic treatment is asso‐
ciated with added volume of work to patients and CF staff and in incremental cost pressure
of CF care.
Two retrospective studies (Sanders et al., 2010; Rosenberg & Scharamm, 1993) found that ad‐
ministration of antibiotics for 14 days in adolescent and young adult CF patients resulted in
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clinical recovery in 72% and 75% of patients respectively. A recent guideline committee for
treatment of CF pulmonary exacerbations that studied the literature of management of exac‐
erbations found no evidence for the optimal duration of treatment of CF pulmonary exacer‐
bations (Flume et al., 2009). The committee recommended that future studies should
examine short and long term subjective and objective outcomes of management of exacerba‐
tions according to duration of treatment.
Risk factors and efficacy of extending the course of antibiotics have been prospectively ex‐
amined (Sequeiros & Jarad, 2012). As in previous studies, nearly 23% of 168 pulmonary ex‐
acerbations in 58 adult CF patients did not recover after 2 weeks of IV antibiotic treatment,
needing extension of duration of treatment. For those prescribed extended courses, most pa‐
tients required additional 7 days of treatment, but some needed doubling of the duration of
treatment (figure 12). Unlike previous studies, a validated symptom score was used and bio‐
markers measured at the end of treatment were examined.
Figure 12. A histogram of the number of patients (Y axis) and duration of treatment for exacerbations for patients
needing extension of IV treatment (X axis). Most patients needed additional 7 days, but some needed at least dou‐
bling the duration of treatment (Adapted from Sequeiros & Jarad, 2012).
Risk factors for extending the IV course were found to be more severe lung disease and per‐
sistent respiratory symptoms and systemic inflammation as assessed by CRP at the end of
treatment. The extension of treatment beyond 14 days resulted in improvement of symp‐
toms, but not of FEV1. Extension of treatment did not result in increased time to the next
exacerbation.
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9. What measurements determine the outcome of CF pulmonary
exacerbations?
The aim of management of CF pulmonary exacerbations is to restore patients to pre-exacer‐
bation clinical status. In most CF centres, determining the end of an exacerbation is done ar‐
bitrarily during clinical consultation.
Sequeiros et al. (2009) examined several clinical parameters throughout the duration of treat‐
ment of exacerbations with IV antibiotics to assess which one best correlated with the pa‐
tient’s clinical picture. These included spirometry, airway calibre and airway resistance
assessed by high frequency test. A novel symptom scoring system was also used, which has
been more recently validated (Jarad & Sequeiros, 2012).
The symptom score was the parameter that changed most frequently at the end of treatment
of exacerbations, more so than FEV1 and FVC (figure 13). As for airway calibre and resist‐
ance, these did not significantly change at the end of exacerbations. Changes in symptom
score correlated with changes in FEV1 and FVC. The authors concluded that the novel
symptom scoring system is sensitive to change with treatment and can be a useful tool for
the assessment of treatment of pulmonary exacerbations.
 
Figure 13. Change after 14 days of IV antibiotics in symptom score (lower score is better health status), FEV1 and FVC
in a cohort of adult CF patients treated for acute pulmonary exacerbations. The symptom score improved in a higher
proportion of patients in comparison with FEV1 and FVC.
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10. Oral corticosteroids as an adjuvant to antibiotics
As discussed above, in addition to excessive bacterial growth, exuberant local lung inflam‐
mation is considered to play an important role in CF pulmonary exacerbations. In this con‐
text, using corticosteroids in addition to antibiotics during the treatment of exacerbations
would be thought to be a logical approach.
Managing exacerbations with corticosteroids and antibiotics is the norm in patients with
COPD. In a prospective study on inpatients with severe COPD who were hospitalised due
to acute exacerbations, Davies et al. (1999) found that adding 30mg prednisolone for 14 days
to usual treatment resulted in improvement of FEV1 and shortening of length of hospital
stay compared with placebo-treated patients.
For CF patients, an open label study found that adding oral corticosteroids resulted in an
improvement of FEV1 in a small cohort of adult CF patients (Dovey et al., 2007). Further‐
more, a national UK survey performed in the authors’ unit, found that all UK CF physicians
had used adjuvant corticosteroids to different extents in managing CF pulmonary exacerba‐
tions (Hester et al., 2007).
This is important because of the increased propensity of CF patients to develop diabetes and
osteoporosis by virtue of the CF disease process. Corticosteroids are bound to adversely af‐
fect the likelihood of these two complications, (increase the incidence and severity), as a sig‐
nificant negative side effect of the drug. To date there are no large trials to answer the
question of whether adding corticosteroids to antibiotics improves outcome of treatment of
CF exacerbations, and the issue remains contentious.
11. Elective courses of antibiotics versus symptomatic treatments
Elective regular administration of IV antibiotics several times per year has been a practice
adopted by many CF teams to improve symptoms and reduce decline in lung function tests.
In a national UK survey of CF centres (Higgs & Jarad, 2005), the authors found that greater
proportion of paediatric patients received regular (elective) courses of IV antibiotics com‐
pared to adult CF patients (figure 14).
This  is  despite  the  fact  that  a  previous  study showed no differences  in  spirometry  im‐
provement  in  patients  who  received  elective  3  monthly  anti-pseudomonal  antibiotic
treatment  compared  to  those  who  received  conventional  symptomatic  treatment,  trig‐
gered  by  increased  symptoms.  The  elective  group  received  an  average  of  4  courses  of
antibiotics  per  year,  compared  with  an  average  of  3  courses  per  year  in  the  sympto‐
matic  group (Elborn et  al.,  2000).
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Figure 14. Larger proportion of paediatric CF patients received elective IV antibiotics in comparison to adult CF pa‐
tients (Higgs & Jarad, 2005).
12. Self-administration of IV antibiotics
Delivery of healthcare for CF patients has changed significantly over the past 20 years. Pre‐
viously all patients were managed in hospital, but there has been a drive for the manage‐
ment of chronic conditions at home. Although not specifically suggested, management of
acute exacerbations of clinical conditions such as COPD, bronchiectasis and CF is also fre‐
quently being done at home.
CF patients with pulmonary exacerbations requiring IV antibiotics place a great strain on
the capacity of hospitals in terms of the available number of beds, on their manpower and
other financial resources with repeated admissions. Accommodation and boarding for pa‐
tients and, sometimes, members of their families account for the largest fraction of hospital
costs for inpatients. Equipment and drugs make up the largest proportion of home therapy
costs (Wolter et al., 1997).
Respiratory Disease and Infection - A New Insight192
Self-administration of antibiotics was first introduced 30 years ago. This practice has been
facilitated by improvement in technology and increased familiarity of patients and CF teams
with antibiotics.
For patients with available peripheral venous access and infrequent exacerbations, antibiot‐
ics are administered via a peripherally inserted central catheter (PIC line) (figure 15). If such
lines are inserted in the non-dominant arm, patients can self-administer their antibiotics.
 
(a) (b) (c) 
Figure 15. Insertion of a PIC line in the left arm of a right handed CF patient. The patient is able to self-administer
antibiotics using his right hand.
Over the years, venous access frequently becomes more difficult to attain due to repeated
use and occlusion of peripheral veins. In such patients, placement of a long-term totally im‐
plantable venous access system is an option. One of these methods, a port-a-cath, consists of
a reservoir surgically inserted under the skin in the upper chest or arm, with the use of seda‐
tion or general anaesthesia. The reservoir is covered by a silicone mesh and appears as a
bump under the skin. It leads to a long venous catheter, which is inserted into a central vein,
usually a subclavian vein, and terminates in the superior vena cava. It is completely internal,
so bathing and swimming are not a problem, although contact sports are contra-indicated
due to risk of trauma and dislodgement of the device (figure 16).
Ports and peripherally inserted lines have their own complications and require specific care,
such anti-septic manipulation and monthly local anticoagulation to prevent blockage from
blot clots. Despite careful maintenance, infection and blockage are not uncommon. Irreversi‐
ble occlusion of ports almost inevitably necessitates complete replacement.
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Figure 16. The port-a-cath. (a): schematic representation of the position of a port-a-cath. (b): accessing the device
chamber by a specifically designed needle. (c) and (d): a needle is inserted into the port-a-cath chamber and a patient
self-administering IV antibiotic via his port-a-cath.
13. Managing cystic fibrosis pulmonary exacerbations at home versus in
hospital
Home therapy is becoming a preferred treatment option for patients with CF suffering from
pulmonary exacerbations in the UK and other parts of the world. With the widespread prac‐
tice of home based IV antibiotic therapy, concern has been expressed by CF healthcare
workers about whether the outcome of care for those treated at home by self-administering
IV antibiotics might be inferior to that of patients treated in hospital.
Hospital management is not favoured by most CF patients, who prefer home therapy (Thorn‐
ton et al., 2005; Pond et al., 1994; Strandvik et al., 1992; Donati et al., 1987). Hospital treatment is
probably disruptive to patients and their families, taking patients away from school or work
commitments and social activities for considerable amounts of time. There are also financial
strains on patients due to earning losses as a result of time off from work and travelling to hos‐
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pital expenses, especially if the treatment centre/hospital is at a considerable distance from the
patient’s home. After numerous admissions throughout their lives, patients and their families
become acquainted with many aspects of IV drug administration and often want to start self-
administration of these medications, avoiding hospital admissions (Gilbert et al., 1988). Rea‐
sons for patients’ preference for home treatment are outlined in table 4.
- Less interruption to education and career
- Reduced earning losses and travelling expenses
- Tastier food
- More facilities to exercise
- Less disruption to sleep
- More convenient timing of drug administration
- Improved quality of life
- Reduced risk of cross infection
- Lack of hospital beds
Table 4. Reasons why patients prefer home IV antibiotic treatment.
The superior outcome of hospital management over home treatment has been attributed to
closer supervision and direct input by the multidisciplinary team, including physiothera‐
pists, dieticians and nursing staff, throughout the period of hospital stay (Thornton et al.,
2004; Pond et al., 1994), ensuring increased adherence to treatment. Albeit unproven, bed
rest during exacerbations has also been widely regarded as another reason for the favoura‐
ble outcome of hospital treatment.
Conversely, there are numerous reasons why home treatment could be clinically less effec‐
tive in treating exacerbations in CF patients (table 5). Considerable commitment is required
from patients who are on home based treatment, as, in addition to their treatment schedules,
they may wish to maintain their domestic routines and social lives, as well as fulfil educa‐
tional and work commitments. Continuing with normal life and not taking time off work or
school would mean maintaining higher general activity levels. These patients are probably
not getting the amount of rest they need as part of their treatment (Thornton et al., 2005).
Self-performed physiotherapy may not be as effective during exacerbations compared to the
treatment provided by a professional physiotherapist and calorie intake may suffer without
daily encouragement (Pond et al., 1994).
- Reduced medical input
- Reduced input from physiotherapists and dieticians
- Reliance on patients to diagnose own complications
- Possible lack of compliance with the IV treatment
- Lack of rest
Table 5. Reasons why healthcare professionals are concerned about the practice of home IV treatment.
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Some antibiotic regimens for home treatment are adapted to make administration more con‐
venient and more compatible with work and school hours (Pond et al., 1994). This includes
twice daily beta-lactam antibiotics versus the recommended thrice-daily regime.
Another important issue is adherence, which is recognised as being potentially poor in CF
(Dodd & Webb, 2000) and may be worse in some patients on home IV treatment. Although
assessed by the multidisciplinary team for competency in terms of self-administration of
drugs, the level of adherence of patients to treatment is not truly known. This is a widely
anecdotally known phenomenon, often revealed when considerable amounts of unused an‐
tibiotics and other drugs are returned by patients and their families to the caring CF centre.
The conflict between patients’ preference for home treatment and health providers’ concern
to achieve a favourable outcome of care during stages of clinical instability in CF is ongoing.
This is currently handled in variable ways by different CF centres. Most centres feel that
they have to offer some kind of home treatment, although a small number do not. Others
prefer a happy medium of starting treatment in hospital and then discharging patients a few
days later to complete the antibiotic course at home. Some CF centres prefer not to treat pa‐
tients at home for two successive exacerbations.
More recently, Collaco et al. (2010) published a large retrospective study with a total of 834
treated exacerbations in both paediatric and adult patients in the United States. They con‐
clude that similar decline in long term FEV1 was observed regardless whether antibiotics
were administered in hospital or at home, with equivalence also found in regards to interval
duration in between successive exacerbation episodes. Interestingly though, subjects treated
in hospital had a statistically significant greater improvement of lung function immediately
after treatment (immediate recovery) in comparison to the home treated group, despite simi‐
lar pre-treatment spirometry. Also, patients treated in hospital had shorter total number of
days of IV antibiotic treatment, implying that patients overcame their exacerbations quicker
when treated in hospital (12.7 days versus 18.9 days), which of course impacts on quality of
life, drug toxicity, antibiotic resistance and healthcare costs.
Given the controversy around this subject,  Sequeiros & Jarad (2010) prospectively exam‐
ined the effect of home treatment with intensive assistance from CF nurses, physiothera‐
pists  and  dieticians  on  patient  outcomes.  The  authors  compared  outcomes  of  this
intensive intervention with outcomes of exacerbations treated at home without intensive
assistance and in hospital.
The study showed that, unlike previous studies, those who were treated in hospital had ini‐
tially poorer quality of life and were underweight compared to those who were treated at,
but these recuperated to match post treatment levels similar to home based patients. The re‐
search also showed that, despite intensive home intervention, outcomes did not differ from
standard home treatment and were inferior to those treated in hospital. The study has been
published in abstract form (Sequeiros & Jarad, 2010) and is presently being prepared as a
full manuscript for publication (figure 17).
Ideally, outcome of care for home treatment should be at least equal to outcome for hospital
treatment and clinical improvement not sacrificed on the basis of economic considerations
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and convenience (Pond et al., 1994). Selection of patients that are considered competent and
safe for self-administered home treatment should be made carefully. A hygienic environ‐
ment and adequate knowledge of preparation and administration of antibiotics should be
ensured, as well as regular physiotherapy, rest and suitable nutrition, which are crucial for
the successful treatment of CF exacerbations. Better still is the availability of support from
family and friends, who are familiar with home treatment methods, as well as from the CF
multidisciplinary team.
Patients need to be aware of the perceived reasons for an inferior outcome of home treat‐
ment and the CF community should definitively address these.
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Figure 17. Changes in FEV1 with treatment of exacerbations treated at home with and without intensive assistance
and in hospital. Best outcome is seen in the hospital treatment group (Sequeiros & Jarad, 2010).
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14. Conclusion
CF  exacerbations  are  complex  and  still  not  completely  understood.  However,  they  re‐
main  an  important  part  of  the  CF  lung  disease  due  to  their  great  negative  impact  on
quality of life, resultant decline in lung function and mortality.
This chapter addresses the natural history, causes and aspects of management, and progno‐
sis of CF exacerbations pertinent mainly to adult CF patients. Until introduction of more ef‐
fective and disease modifying treatments for CF, better understanding and management of
CF exacerbations remain an important goal for the CF community.
Prevention, accurate identification and treatment of pulmonary exacerbations are key to the
improved survival and quality of life of CF patients. Efforts should be made to standardize
treatments and ensure high standards of care throughout different CF centres worldwide.
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